Clinical Trials Logo

Plasma Cell Myeloma Refractory clinical trials

View clinical trials related to Plasma Cell Myeloma Refractory.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06356571 Not yet recruiting - Clinical trials for Plasma Cell Myeloma Refractory

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

SubQSA
Start date: June 11, 2024
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.